Filing Details
- Accession Number:
- 0001144204-15-060242
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-10-21 16:31:09
- Reporting Period:
- 2015-10-19
- Filing Date:
- 2015-10-21
- Accepted Time:
- 2015-10-21 16:31:09
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1369868 | China Biologic Products Inc. | CBPO | Biological Products, (No Disgnostic Substances) (2836) | 752308816 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1331795 | David Gao | 18Th Floor, Jialong International Building, 19 Chaoyang Park Road Beijing F4 100125 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2015-10-19 | 200 | $105.03 | 616,800 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-10-20 | 258 | $105.00 | 616,542 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- Represents 458 shares of common stock sold through a trading plan (the "10b5-1 Plan") adopted by the Reporting Person on September 14, 2015 that complies with the requirements of Rule 10b5-1(c)(1) under the Securities Exchange Act of 1934, as amended. The Reporting Person intends to use the proceeds from the sales effected under the 10b5-1 Plan to pay income tax due in connection with the scheduled vesting of certain restricted stock held by the Reporting Person and the exercise of certain stock options held by the Reporting Person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in the open market at prices ranging from $105.020 to $105.030, inclusive. The Reporting Person undertakes to provide to any security holders of the Issuer or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Footnote 2.